At Cedar, we believe in the vision that population health and welfare are enhanced by the development and diffusion of innovative healthcare technologies.
To promote this vision, we conduct evidence-based research on the comparative value of health care technologies. For the past two decades, our research has paved the way for breakthrough drugs, devices, and diagnostics to play effective roles in various health care settings.
Our leadership has a unique blend of experience that combines medical and academic training with a pragmatic understanding of challenges of research, and best practices for innovation adoption. Success hinges on a collaborative model, which we find includes payers, providers, key opinion leaders, and medical policy organizations.
After undergoing radial prostatectomy (RP), patients remain at risk of metastasis. An individualized genomic classifier (GC) test designed to predict metastases significantly changes urologists’ adjuvant treatment recommendations for post-operative patients with prostate cancer. Published in Current Medical Research and Opinion, this study provides evidence for the utility of the GC test, and shows that it may guide the use of adjuvant radiation.